{
  "0": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including CT follow-up intervals and the general lack of need for routine post-op radiotherapy in early-stage NSCLC. However, it incorrectly states that the follow-up frequency does not need adjustment after radiotherapy, whereas the reference answer specifies that radiotherapy patients require more frequent follow-up (every 3–6 months for 3 years)."
  },
  "1": {
    "score": 2.0,
    "explanation": "2: The model answer recommends routine use of head MRI and FDG-PET/CT in this scenario, which contradicts the reference answer stating these are not recommended for routine surveillance without symptoms or clear imaging indications. The model answer also introduces additional content (biopsy, molecular testing) not directly relevant to the imaging question, reflecting notable errors and limited alignment with the reference."
  },
  "2": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion and some supporting evidence, but it incorrectly states that the follow-up frequency for I期放疗患者应与手术±化疗者一致，未体现放疗组需更密集随访的要点，且未准确区分两组的具体随访间隔，存在重要内容遗漏。"
  },
  "3": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, emphasizing that routine FDG-PET/CT or brain MRI is not recommended without suspicious clinical or imaging findings. However, it provides more detail than required and introduces some stratification and risk factors not explicitly mentioned in the reference, which, while accurate, slightly diverges from the concise focus of the reference answer."
  },
  "4": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, including guideline-based recommendations, supporting evidence, and exceptions, fully aligning with the reference answer without omissions or errors."
  },
  "5": {
    "score": 3.0,
    "explanation": "3: The model answer provides a partial and nuanced discussion, correctly emphasizing the palliative intent and multidisciplinary evaluation, but it overstates the appropriateness of surgery as a palliative option, whereas the reference answer clearly states surgery should not be directly considered and prioritizes systemic/palliative therapy."
  },
  "6": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining that routine brain MRI is not recommended in this scenario, and providing appropriate rationale and management steps without omissions or errors."
  },
  "7": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and provides additional relevant clinical reasoning and guideline support without introducing errors or omissions."
  },
  "8": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed discussion but directly contradicts the reference answer by stating that systemic therapy decisions remain valid without metastatic site pathology, which is a notable error. While it covers relevant considerations, it omits the key requirement for pathological confirmation of metastases before systemic therapy, as emphasized in the reference answer."
  },
  "9": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends adjuvant chemotherapy for a 21-gene recurrence score of 25, which is below the threshold (≥26) for clear chemotherapy benefit per guidelines. This is a notable error, despite otherwise comprehensive coverage."
  },
  "10": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and technically accurate discussion of re-irradiation, including patient selection, technical considerations, and risks, but it omits the key point from the reference answer that re-irradiation is generally not recommended due to high risk, and that systemic therapy should be prioritized."
  },
  "11": {
    "score": 3.0,
    "explanation": "3: The model answer provides a partial and somewhat accurate discussion but overemphasizes局部治疗 as优先, which contradicts the reference answer’s clear recommendation to优先考虑全身系统治疗 after局部控制. It also introduces unnecessary complexity and does not clearly state that单纯局部治疗不足以替代全身治疗, leading to some clinical inaccuracy and omission of the key guideline."
  },
  "12": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but contradicts the reference answer by stating that T-DXd should not be directly prioritized in HER2-mutant squamous cell carcinoma, whereas the reference answer affirms its use regardless of histological subtype. This represents a notable error in clinical guidance."
  },
  "13": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and references guidelines, but it incorrectly recommends routine FDG-PET/CT for asymptomatic imaging abnormalities, which contradicts the reference answer's stance against routine advanced imaging in the absence of clinical or strong radiological suspicion. This is a significant deviation, though the rest of the content is relevant."
  },
  "14": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion but incorrectly prioritizes PD-L1 testing over comprehensive molecular testing, whereas the reference states both should be performed in parallel and are equally important for initial treatment decisions. There are also some omissions regarding the guideline's emphasis on not deprioritizing molecular testing."
  },
  "15": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "16": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that same-side, different-lobe nodules are not T3, but incorrectly states they are M1a (stage IV), which is outdated; according to the 8th edition TNM, same-side, different-lobe nodules are T4, not M1a. This is a significant inaccuracy, though the answer shows partial understanding of the staging principles."
  },
  "17": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, but it introduces additional details (如PD-L1分层、指南依据、流程优化等) beyond the reference answer and slightly overemphasizes等待分子检测结果期间的处理，这些虽有参考价值但并非核心要点。整体内容无重大遗漏或错误。"
  },
  "18": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points from the reference answer, emphasizing that molecular testing is recommended for all NSCLC subtypes, including squamous cell carcinoma. However, it introduces additional clinical nuances and considerations that, while accurate, slightly complicate the directness of the reference answer and may imply more selectivity than the reference's unequivocal recommendation."
  },
  "19": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and references guidelines, but it contradicts the reference answer by recommending annual CT after 2 years, omitting the standard recommendation to continue 6-monthly CT until 3 years post-op. This is a significant deviation from the reference standard."
  },
  "20": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including the appropriateness of larotrectinib as first-line therapy, CNS activity, guideline recommendations, and considerations for brain metastases management, with no major omissions or errors."
  },
  "21": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage, guideline support, clinical trial data, and key caveats, with no major omissions or errors."
  },
  "22": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the rationale for prioritizing local treatment and the necessity of systemic therapy, but it introduces more detail than required and slightly blurs the priority by emphasizing combined therapy rather than clearly stating local treatment should be prioritized first. Minor omissions in directly stating the sequence as in the reference answer."
  },
  "23": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced, guideline-based approach, but it introduces conditional scenarios (e.g., early switch in case of progression/toxicity) that are not explicitly stated in the reference answer, which more strictly recommends waiting until completion or interruption of the current regimen before starting osimertinib. Minor deviation from the strict protocol accounts for the point deduction."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the clinical content of the reference answer and expands with relevant guidelines, study data, and clinical considerations, without introducing errors or major omissions."
  },
  "25": {
    "score": 4.0,
    "explanation": "4: The model answer covers most key points, including differences in follow-up frequency and imaging focus, and references guideline recommendations. However, it lacks precise details on the exact timing for follow-up in later years and does not specify the transition to annual low-dose CT, as stated in the reference answer."
  },
  "26": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including the need for orthopedic stabilization and palliative radiotherapy alongside systemic therapy, but it introduces more nuance and conditional recommendations than the reference answer, which states these interventions should be routinely combined. Minor omissions include less emphasis on the non-substitutability of local interventions by systemic therapy."
  },
  "27": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it introduces more nuanced stratification and guideline details, which, while accurate, go slightly beyond the scope of the reference. There are no major omissions, but the answer could be more concise and directly reflect the reference's emphasis on routine follow-up without additional imaging unless suspicion arises."
  },
  "28": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail, guideline support, and appropriate prioritization of reoperation plus systemic therapy, with no major omissions or errors."
  },
  "29": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and references guidelines, but it inaccurately states that low-dose non-contrast CT is recommended in the first 2–3 years, whereas the reference answer clarifies that standard (not low-dose) CT is required during this period. This is a significant omission, leading to partial but not complete alignment."
  },
  "30": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but directly contradicts the reference answer by recommending immediate switch to BRAF/MEK inhibitors, whereas the reference recommends completing current therapy unless toxicity or progression occurs. This is a notable error despite the comprehensive discussion."
  },
  "31": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and includes some relevant details, but it contradicts the reference answer by recommending continuation of the original follow-up schedule despite new radiological abnormalities, which is a significant clinical inaccuracy. It also omits the need for increased imaging frequency as emphasized in the reference answer."
  },
  "32": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and guideline-based rationale but incorrectly states that routine preoperative brain MRI is not recommended for T2aN0M0 central-type NSCLC, whereas the reference answer affirms it is recommended due to higher risk in central lesions. This represents a significant omission and a key inaccuracy regarding current recommendations for this specific clinical scenario."
  },
  "33": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, providing additional detail and justification. However, it slightly overstates the guideline evidence level (NCCN 1 vs. 2B) and adds content not strictly required, but there are no major omissions or errors."
  },
  "34": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses both the acute management of SVCS and the need for definitive tumor control, and aligns fully with the reference answer without omissions or errors."
  },
  "35": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately reflects guideline recommendations, emphasizing that neoadjuvant therapy is not routinely indicated for this tumor size but may be considered with high-risk features. However, it provides more detail than the reference answer and slightly overemphasizes individualization, which, while reasonable, is not the main point of the reference answer. Minor deviation from the strict guideline focus prevents a perfect score."
  },
  "36": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable summary of guideline recommendations but inaccurately suggests that annual CT can begin immediately after 2 years, whereas the reference answer specifies that 2–3 years of 6-monthly CT is standard before switching to annual scans. This is a significant omission regarding the timing of frequency adjustment."
  },
  "37": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion but incorrectly states that neoadjuvant therapy is not limited to HER2-positive or triple-negative subtypes in cT1cN0M0 patients, which contradicts the reference answer. There are some accurate points, but the main clinical indication is misrepresented."
  },
  "38": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, emphasizing initial local management of the effusion and subsequent systemic therapy. However, it introduces the option of early concurrent systemic therapy and more nuanced sequencing, which, while evidence-based, slightly diverges from the reference's clear prioritization of local control first."
  },
  "39": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion but diverges from the reference by recommending a more intensive follow-up schedule, which is not supported by the reference answer. It introduces some inaccuracies regarding guideline recommendations and overstates the need for increased surveillance, leading to partial but not complete alignment."
  },
  "40": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach and covers key points about stable radiological findings and when to increase surveillance, but it omits the reference answer’s emphasis on increasing imaging frequency for any repeated radiological abnormalities, even if asymptomatic, and is more conservative than guideline recommendations."
  },
  "41": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail on the rationale, recommended endocrine strategies, and the role of chemotherapy, with no major omissions or errors."
  },
  "42": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes surgery as the first-line treatment, which contradicts current guidelines that recommend concurrent chemoradiotherapy as standard for stage IIIA (T3N1) NSCLC. While the answer is detailed, this major error significantly affects its accuracy."
  },
  "43": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding, referencing guidelines and individualization, but it does not clearly state that随访频率应适当增加（如3个月内复查CT）是推荐做法，且在结论部分对“常规随访”与“短期复查”表述略显模糊，未完全强调应超出常规间隔。"
  },
  "44": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion but introduces several points (such as mandatory repeat pathological assessment and guideline recommendations) that contradict the reference answer, which states that repeat pathological assessment is not routinely required if initial assessment was done and imaging shows no progression. There are also some inaccuracies regarding guideline interpretation."
  },
  "45": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and cites some guidelines, but it incorrectly prioritizes low-dose non-contrast CT every 6 months as the standard, omitting that the first 2–3 years should use regular (possibly contrast-enhanced) CT every 3–6 months per the reference answer. This is a significant deviation from the recommended surveillance protocol."
  },
  "46": {
    "score": 2.0,
    "explanation": "2: The model answer contains notable errors, as it incorrectly states that treatment can proceed without pulmonary function assessment, which contradicts the reference answer's emphasis on the necessity of PFTs before chemoradiotherapy due to safety concerns. While the model answer discusses alternative assessments and multidisciplinary care, it omits the critical point that treatment should be delayed until pulmonary function is adequately evaluated."
  },
  "47": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional relevant details, and contains no major omissions or errors."
  },
  "48": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding, but it does not explicitly强调“必须明确病理类型后才能依赖检测结果指导治疗”这一核心点，且对炎性癌的适用性表述略显模糊。"
  },
  "49": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for combining SVC stenting with concurrent chemoradiotherapy, and appropriately noting when stenting alone is indicated. No major omissions or errors are present."
  },
  "50": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, evidence-based, and covers all key clinical points in the reference answer, with no major omissions or errors. It expands on the rationale, supporting evidence, and individualized considerations, fully aligning with the reference content."
  },
  "51": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of treatment options and includes relevant guidelines, but it incorrectly prioritizes reoperation as the first choice, which contradicts the reference answer. This is a significant inaccuracy, though the rest of the content is generally appropriate."
  },
  "52": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage, correctly discussing the need for ongoing surveillance and referencing guidelines, but it incorrectly suggests maintaining the standard follow-up frequency rather than increasing it in the presence of persistent abnormal imaging, which is a key point in the reference answer."
  },
  "53": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical decision points, including guideline references and the need for individualized assessment in pT1aN1mi cases. However, it does not clearly state that for tumors <0.6 cm, there is insufficient evidence to routinely recommend adjuvant chemotherapy plus trastuzumab, as emphasized in the reference answer."
  },
  "54": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding, referencing guidelines and alternative staging methods. However, it does not emphasize as strongly as the reference answer that PET/CT is the standard of care and should ideally be performed preoperatively, making the recommendation for direct surgery less cautious than the reference. Minor omissions in stressing the standard workflow prevent a perfect score."
  },
  "55": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, providing detailed rationale, guideline support, and practical considerations without any major omissions or errors."
  },
  "56": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediate FDG-PET/CT, which contradicts the reference answer's guidance to prioritize increased imaging follow-up frequency in asymptomatic patients with non-specific nodules. While the model provides rationale and some relevant considerations, it contains a notable error in management approach."
  },
  "57": {
    "score": 4.0,
    "explanation": "4: The model answer is comprehensive and accurate, covering the indications and evidence for both pembrolizumab and olaparib, and provides a logical approach to sequencing. However, it suggests a preference for completing pembrolizumab before considering olaparib, whereas the reference answer emphasizes that there is no clear priority and that the choice should be individualized, which is a minor but important omission."
  },
  "58": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing detailed guideline-based recommendations and explicitly stating that 3–6 month CT intervals are unnecessary for this group, with no major omissions or errors."
  },
  "59": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends RET抑制剂为首选 for squamous NSCLC with RET rearrangement, which contradicts current guidelines and evidence that prioritize standard chemotherapy due to limited data in this population. While the answer is detailed, it contains a notable clinical error and overstates the applicability of RET inhibitors in squamous histology."
  },
  "60": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "61": {
    "score": 2.0,
    "explanation": "2: The model answer recommends a stricter, III期-like follow-up for IIB期 patients with all lesions resected, which contradicts the reference answer that supports I–II期 follow-up in this scenario. The model answer overstates recurrence risk and omits the reference's key point that, in the absence of additional high-risk features, standard I–II期 surveillance is sufficient."
  },
  "62": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and includes relevant clinical reasoning, but it inaccurately suggests abemaciclib as a reasonable alternative, which contradicts the reference answer stating there is no direct evidence or recommendation for substitution. It also introduces extra discussion not present in the reference, leading to some inaccuracies."
  },
  "63": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive discussion but diverges from the reference answer by suggesting re-operation as the first choice if feasible, whereas the reference answer clearly prioritizes chemoradiotherapy over re-operation. This represents a significant difference in clinical recommendation, though the model answer covers relevant considerations and guidelines."
  },
  "64": {
    "score": 3.0,
    "explanation": "3: The model answer provides detailed follow-up schedules and considerations but incorrectly states that increased imaging frequency is not needed for asymptomatic residual abnormalities, which contradicts the guideline-based recommendation in the reference answer. This represents a significant omission in clinical content."
  },
  "65": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional supporting evidence and rationale, and no major omissions or errors."
  },
  "66": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale for performing molecular testing, but it contradicts the reference answer's main point that such testing is of limited value and not routinely required in this scenario. The model answer overemphasizes the necessity of testing, missing the reference's focus on palliative care and the limited role of molecular diagnostics in this context."
  },
  "67": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed guideline-based recommendations, but it introduces some nuance about individualization and high-risk features that, while accurate, slightly complicates the clear distinction made in the reference answer regarding standard follow-up intervals. The main point—that surgical patients are generally followed every 6 months, not every 3–6 months as with radiotherapy—is present."
  },
  "68": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and references relevant studies, but it inaccurately suggests that ALND can be omitted in some cases with 3 SLN-positive nodes, which is outside current standard guidelines and the reference answer's clear recommendation. This represents a notable deviation from accepted practice."
  },
  "69": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive discussion but incorrectly prioritizes concurrent chemoradiotherapy over surgery for T4N1M0, whereas the reference answer states surgery can be considered first if resectable. There are some accurate details, but the main recommendation diverges from the reference, leading to partial credit."
  },
  "70": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of current guidelines and management, but it omits the key point from the reference answer: preoperative axillary assessment (at least by ultrasound) is a mandatory step before neoadjuvant therapy, and the process cannot proceed without this documented evaluation, regardless of whether biopsy is performed."
  },
  "71": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the rationale for switching to osimertinib, guideline recommendations, and practical considerations. However, it introduces additional details and caveats not present in the reference answer, which, while accurate, slightly diverge from the concise focus of the reference. No major omissions or errors are present."
  },
  "72": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and provides additional guideline-based rationale and evidence without introducing errors or omissions."
  },
  "73": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediately switching to an ALK inhibitor, which contradicts the reference answer that advises completing the current systemic therapy before switching. While the model provides rationale and evidence, it contains a notable error in clinical decision-making, leading to a limited but not entirely irrelevant response."
  },
  "74": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes local brain radiotherapy as the initial treatment, whereas current guidelines and the reference answer recommend systemic therapy as the primary approach, with local therapy considered based on symptoms and lesion characteristics. While the model answer is detailed and covers relevant options, this key error in treatment sequencing represents a notable deviation from standard recommendations."
  },
  "75": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of both systemic and local therapies, but it incorrectly prioritizes systemic therapy as the initial treatment, whereas the reference answer clearly states that local treatment of brain metastases should be prioritized first. This represents a significant deviation from the recommended sequence, despite otherwise comprehensive content."
  },
  "76": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of nodule assessment and incorporates guidelines, but it underemphasizes the heightened suspicion and need for more aggressive evaluation in patients with a history of colorectal cancer, as highlighted in the reference answer. It suggests that routine follow-up may still be appropriate in some cases, which is a notable omission given the reference's clear recommendation against routine follow-up in this context."
  },
  "77": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, expands on the rationale, and provides additional relevant details without introducing errors or omissions."
  },
  "78": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, provides additional rationale and evidence, and has no major omissions or errors."
  },
  "79": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based reasoning, but it contradicts the reference answer by stating that routine invasive mediastinal staging is not recommended in these patients, whereas the reference answer suggests it should still be considered. This represents a minor but important omission in alignment with the reference."
  },
  "80": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed discussion but contains a notable error: it incorrectly states that the imaging follow-up frequency should be the same for patients receiving postoperative radiotherapy as for those receiving surgery±chemotherapy, whereas the reference answer clearly states that follow-up should be more frequent after radiotherapy."
  },
  "81": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes palliative radiotherapy over concurrent chemoradiotherapy due to severe COPD, and provides detailed rationale, matching the reference answer with no major omissions or errors."
  },
  "82": {
    "score": 2.0,
    "explanation": "2: The model answer recommends routine FDG-PET/CT and brain MRI for all such cases, which contradicts the reference answer stating these should only be performed when there is strong suspicion or symptoms of recurrence. This represents a notable error in clinical guidance, despite providing detailed rationale."
  },
  "83": {
    "score": 3.0,
    "explanation": "3: The model answer provides a well-reasoned argument for SRS and includes supporting evidence, but it contradicts the reference answer's clear prioritization of surgery as first-line when feasible. It omits the reference's emphasis on surgery for symptomatic lesions or pathological diagnosis and overstates SRS as the default, which is not fully aligned with current guidelines for this scenario."
  },
  "84": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes enhanced chest CT as first-line, and clearly explains the rationale and subsequent steps, fully matching the reference answer with no significant omissions or errors."
  },
  "85": {
    "score": 2.0,
    "explanation": "2: The model answer directly contradicts the reference answer by stating that capmatinib and tepotinib are suitable for all NSCLC subtypes including squamous cell carcinoma, whereas the reference answer clearly states that evidence and guidelines do not support their use in squamous cell carcinoma. This is a notable error in clinical content."
  },
  "86": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer and adding relevant guideline-based details without introducing errors or omissions."
  },
  "87": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of management options and relevant studies, but it overemphasizes术后系统性治疗作为常规推荐，而参考答案明确指出系统性治疗仅为2B类推荐、并非优先选项。模型答案对直接观察的适用范围描述不够准确，且未突出“术后无残留且无远处转移时可选择密切观察”这一核心要点。"
  },
  "88": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical points, including the indication for endocrine therapy, the impact of liver dysfunction, and the need for individualized decision-making. However, it introduces more detail than the reference answer and slightly overemphasizes withholding endocrine therapy in severe liver dysfunction, whereas the reference answer maintains that endocrine therapy remains the first choice with dose/drug adjustment. Minor differences in emphasis and detail account for the deduction."
  },
  "89": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, emphasizing the priority of local therapy for oligometastatic NSCLC and the integration of systemic therapy. However, it introduces more detail than required and slightly complicates the main recommendation, which is to prioritize local therapy (with or without systemic therapy) rather than suggesting an equal choice between the two. Minor over-elaboration prevents a perfect score."
  },
  "90": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with additional guideline and evidence details, and no major omissions or errors."
  },
  "91": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of follow-up principles and mentions guidelines, but it incorrectly states that follow-up frequency does not depend on prior radiotherapy, which contradicts the reference answer. There are some omissions regarding the specific follow-up intervals based on treatment modality."
  },
  "92": {
    "score": 3.0,
    "explanation": "3: The model answer provides a structured and partially accurate approach, but it overemphasizes早期使用FDG-PET/CT和增强CT，并未明确指出“常规不推荐立即增加FDG-PET/CT或脑MRI”，且对影像学异常的处理与参考答案有一定出入，存在部分不准确和遗漏。"
  },
  "93": {
    "score": 2.0,
    "explanation": "2: The model answer directly contradicts the reference answer by recommending immediate initiation of ALK抑制剂 and skipping the remainder of chemotherapy, which is a notable error. While it provides supporting evidence and rationale, it fails to align with the guideline-based approach described in the reference answer."
  },
  "94": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly classifies the scenario as a single primary with metastasis (单发转移性病灶) rather than two primary lung cancers, which is the key point in the reference answer. While it provides detailed treatment options, the fundamental error in diagnosis and staging leads to a notable clinical inaccuracy."
  },
  "95": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates nuanced understanding, but it overemphasizes selective testing and underplays the current trend toward broad molecular profiling in all advanced NSCLC, including squamous cell carcinoma, as recommended in the reference answer. Minor omissions include not explicitly stating that broad molecular and PD-L1 testing is recommended for all advanced NSCLC patients."
  },
  "96": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed discussion but contradicts the reference answer by recommending routine imaging restaging and brain MRI, which the reference states is not required unless new abnormalities are found. This represents a notable error in clinical content."
  },
  "97": {
    "score": 5.0,
    "explanation": "5: The model answer provides all the key clinical content from the reference answer, with additional supporting evidence and practical considerations, and contains no major omissions or errors."
  },
  "98": {
    "score": 3.0,
    "explanation": "3: The model answer provides a well-argued rationale for prioritizing targeted therapy, citing supporting evidence and discussing both options, but it directly contradicts the reference answer, which recommends whole-brain radiotherapy as the initial treatment. The model omits the reference's emphasis on rapid symptom control and stabilization as the primary goal, leading to a significant clinical divergence."
  },
  "99": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of ceritinib's use, efficacy, and safety, but incorrectly states that ceritinib is not of equal priority, which contradicts the reference answer. It also introduces additional considerations not required by the question, leading to partial but not complete alignment."
  },
  "100": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediate advanced imaging (FDG-PET/CT and brain MRI) for any residual or new lesion, which contradicts the reference answer's guidance that such imaging is not routinely recommended without clear signs of recurrence. The model answer overstates the need for aggressive imaging and does not align with standard follow-up protocols, representing a notable error."
  },
  "101": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale against using CT随访/观察作为同等可选方案, which directly contradicts the reference answer that states随访观察可以作为系统治疗的可选方案之一（在特定条件下）。因此，模型答案存在明显的内容偏差和错误，未能准确反映参考答案的核心观点。"
  },
  "102": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it introduces additional stratification and details (如原发/转移性、分子特征、指南等) beyond the reference answer, which, while accurate, slightly diverges from the concise focus of the reference. The core message—that系统治疗不能直接替代局部治疗评估—is preserved, with only minor omissions in emphasizing优先考虑局部治疗。"
  },
  "103": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale for more frequent follow-up (every 3–6 months) based on R1/R2 resection status, but this contradicts the reference answer, which recommends every 6 months for this patient group. The model overemphasizes the need for increased frequency without aligning with standard recommendations for IIA (T2bN0) patients post-surgery and adjuvant chemotherapy, leading to partial accuracy."
  },
  "104": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating on guideline support, rationale, and exceptions without introducing errors or omissions."
  },
  "105": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes HER2-targeted therapy over immunotherapy, provides supporting evidence, and addresses nuances such as patient preference and clinical context, with no major omissions or errors."
  },
  "106": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, with additional detail and no major omissions or errors. It accurately prioritizes MET抑制剂, explains the rationale, and addresses exceptions, fully aligning with the reference."
  },
  "107": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale for using amivantamab-vmjw monotherapy and cites supporting guidelines, but it inaccurately states that monotherapy is a reasonable initial choice, which contradicts the reference answer's clear recommendation against this approach. This represents a significant clinical inaccuracy despite otherwise comprehensive coverage."
  },
  "108": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends RET抑制剂 as first-line therapy for鳞状非小细胞肺癌 with RET重排, whereas current evidence and guidelines support chemotherapy as the standard first-line treatment due to limited data for RET inhibitors in squamous histology. The answer demonstrates notable errors and misinterpretation of guideline recommendations."
  },
  "109": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points about prioritizing local therapy for oligometastatic disease, but it introduces combined local and systemic therapy as the preferred approach, which is a minor deviation from the reference answer that emphasizes local therapy as the first choice. The model also provides additional details and context, but the core recommendation is slightly broader than the reference."
  },
  "110": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical decision points, including the distinction between T4 and double primary lung cancer, relevant investigations, and treatment principles. However, it introduces more detail than the reference answer and slightly overemphasizes the need for pathological confirmation and MDT discussion, which, while appropriate, are not explicitly required by the reference answer. Minor omissions include not clearly stating that only contralateral lesions should be considered for double primary lung cancer management."
  },
  "111": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with additional evidence and guideline support, and no major omissions or errors."
  },
  "112": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of the clinical context and the potential utility of FDG-PET/CT, but it incorrectly states that FDG-PET/CT is routinely appropriate, whereas the reference answer emphasizes that routine use is not supported and should be reserved for cases with confirmed or highly suspicious findings. This represents a significant deviation from the reference answer's core recommendation."
  },
  "113": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of follow-up imaging and includes relevant guidelines, but it omits the key point that for IIB NSCLC within the first 2–3 years postoperatively, enhanced CT (with or without contrast) every 6 months is recommended even if asymptomatic. It incorrectly suggests that low-dose non-contrast CT alone is sufficient, which is not in line with the reference answer."
  },
  "114": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing clinical follow-up over immediate surgery, and addresses exceptions and monitoring, with no major omissions or errors."
  },
  "115": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including patient selection, evidence, guideline recommendations, and rationale for prioritizing KRAS G12C inhibitors regardless of PD-L1 status, with no major omissions or errors."
  },
  "116": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects guideline recommendations, and covers all key points from the reference answer without major omissions or errors. It even expands on decision-making criteria and rationale, fully aligning with the reference content."
  },
  "117": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, emphasizing enhanced chest CT as the first-line evaluation and reserving PET/CT and brain MRI for specific indications. However, it provides more detail than required and could be more concise, slightly deviating from the reference answer's focus on not routinely recommending PET/CT or brain MRI."
  },
  "118": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the follow-up CT frequency is the same for both groups, whereas the reference answer clearly states that patients who received radiotherapy require more frequent CT scans than those who had surgery alone. This is a notable error, despite the otherwise detailed content."
  },
  "119": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional guideline-based justification and practical details without introducing inaccuracies."
  },
  "120": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced, guideline-based discussion, but it introduces individualized decision-making and possible omission of radiotherapy in select low-risk patients, which is more permissive than the reference answer's clear recommendation to consider chest wall radiotherapy due to persistent local recurrence risk. Minor omissions include not emphasizing that radiotherapy should not be omitted outright in this scenario."
  },
  "121": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based discussion, but it emphasizes afatinib as the preferred option per current guidelines, whereas the reference answer states osimertinib can be prioritized. This represents a minor difference in prioritization, though the clinical content is otherwise accurate and comprehensive."
  },
  "122": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale and references guidelines, but it contradicts the reference answer by stating that postoperative PET/CT is not necessary if preoperative assessment was adequate, whereas the reference answer clearly states that PET/CT should be performed postoperatively if it was missed preoperatively. This represents a significant clinical disagreement."
  },
  "123": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive discussion but places undue emphasis on systemic therapy as the initial approach, which differs from the reference answer's recommendation to prioritize local therapy assessment first. It also introduces additional details (e.g., molecular subtypes, trial data) that, while relevant, do not directly address the core clinical decision as outlined in the reference answer."
  },
  "124": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including guideline recommendations, patient selection, and supporting evidence. However, it is more detailed than the reference and introduces additional considerations (e.g., genetic status, PS评分、MDT流程) that, while accurate, slightly diverge from the concise focus of the reference answer. No major omissions or errors are present."
  },
  "125": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, emphasizing selective use of PET/CT and brain MRI rather than routine application. However, it provides more detailed stratification and practical steps, which, while accurate, slightly expands beyond the concise focus of the reference answer. No major omissions or errors are present."
  },
  "126": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "127": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of EGFR S768I mutation and current evidence, but it omits the key point from the reference answer that erlotinib, gefitinib, or dacomitinib can be considered as first-line therapy based on molecular subtype rather than histology. Instead, it incorrectly deprioritizes these agents and recommends osimertinib as first-line, which is not aligned with the reference answer."
  },
  "128": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, correctly recommending 6-monthly CT for 2–3 years and annual thereafter, and not supporting 3–6 monthly scans unless high-risk features are present. However, it includes some additional details (e.g., LDCT for contralateral lung, PET-CT/MRI) not directly relevant to the core question, which slightly detracts from focus."
  },
  "129": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of current guidelines and clinical reasoning but omits the key point from the reference answer that bronchoscopy is an important initial step and should be performed before considering invasive mediastinal lymph node assessment. It incorrectly suggests bronchoscopy is not routinely required, which is a notable deviation."
  },
  "130": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the rationale for testing, guideline recommendations, and clinical implications, with no major omissions or errors."
  },
  "131": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion and some clinical rationale, but it incorrectly states that pathological confirmation of N3 can proceed without prior PFTs or PET-CT, which contradicts the reference answer’s emphasis on completing these assessments first. There are also some omissions regarding the necessity of a complete staging and functional evaluation before invasive procedures."
  },
  "132": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and nuanced discussion but omits the clear, guideline-based recommendation that pathological mediastinal lymph node evaluation should still be routinely performed for accurate staging and treatment planning, as stated in the reference answer. The model answer instead suggests individualization and downplays the necessity, which is a significant omission."
  },
  "133": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, elaborates on guideline support, treatment options, and practical considerations, with no major omissions or errors."
  },
  "134": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, emphasizing that routine FDG-PET/CT or brain MRI is not recommended without symptoms or high suspicion. However, it provides more detailed stratification and scenarios, which, while accurate, slightly extends beyond the concise focus of the reference answer. No major errors or omissions are present."
  },
  "135": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive, stepwise approach and includes additional considerations (e.g., immunotherapy, other targets), but it omits the clear prioritization of systemic chemotherapy as the first-line when TRK inhibitors are contraindicated, as stated in the reference answer. This introduces some inaccuracy regarding the recommended treatment sequence."
  },
  "136": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "137": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale for maintaining the standard 6-month follow-up, but this directly contradicts the reference answer, which clearly states that imaging frequency should be increased for any new or residual radiological abnormality, even if stable and asymptomatic. This is a notable error in clinical management."
  },
  "138": {
    "score": 2.0,
    "explanation": "2: The model answer overstates the necessity of brain MRI in asymptomatic, early-stage (T2aN0) NSCLC patients, incorrectly stating it is mandatory per guidelines, whereas the reference answer correctly notes it is optional unless neurological symptoms are present. This represents a notable error in guideline interpretation."
  },
  "139": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the clinical content of the reference answer, with additional supporting evidence, relevant studies, and a nuanced discussion of decision factors, without any major omissions or errors."
  },
  "140": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine FDG-PET/CT, which contradicts the reference answer stating it should not be done routinely. While the model provides some relevant information, it contains a notable error in clinical decision-making and overstates the guideline indications."
  },
  "141": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale for recommending adjuvant chemotherapy, which contradicts the reference answer and current guidelines for pT1aN0 triple-negative breast cancer, even with micropapillary features. It overstates the need for adjuvant therapy and omits the guideline-based recommendation for observation, representing a notable error."
  },
  "142": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that routine brain MRI is recommended for follow-up in asymptomatic patients, which contradicts the reference answer and current guidelines. While it provides some relevant rationale, it contains a notable error regarding the indication for MRI, leading to a limited but not entirely irrelevant response."
  },
  "143": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach and references guidelines, but it recommends a shorter follow-up interval (every 3–6 months, sometimes every 3 months) for R1/R2 patients, which is not supported by the reference answer that states there is no evidence for shorter intervals even with positive margins. This is a significant deviation from the reference standard."
  },
  "144": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including the need to increase imaging follow-up frequency in the presence of suspicious radiological abnormalities, even if asymptomatic. However, it introduces additional guideline details and risk stratification not explicitly mentioned in the reference answer, and suggests some scenarios where routine follow-up may be sufficient, which slightly diverges from the reference's more direct recommendation."
  },
  "145": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and structured approach but prioritizes systemic therapy over chest radical chemoradiotherapy, which contradicts the reference answer's emphasis on chest radical chemoradiotherapy as the first choice after intracranial control. There are some accurate points, but the treatment sequence and logic differ from the reference, resulting in partial coverage with notable omissions."
  },
  "146": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including immediate initiation of systemic therapy despite missing molecular results, the need to complete molecular testing as soon as possible, and provides additional guideline-based rationale and treatment options without introducing errors."
  },
  "147": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a well-reasoned, guideline-based justification for omitting chemotherapy and 21-gene testing in this low-risk patient. However, it slightly diverges from the reference answer, which emphasizes the need to consider 21-gene testing for all >0.5 cm, pN0, HR+/HER2- cases, whereas the model answer suggests it is not necessary in T1aN0 patients, reflecting a minor omission in the strict application of the reference standard."
  },
  "148": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine FDG-PET/CT for all patients with imaging abnormalities, which contradicts the reference answer stating these should not be done routinely without clear evidence of recurrence. While the answer is detailed, it contains notable errors regarding the indications for advanced imaging."
  },
  "149": {
    "score": 3.0,
    "explanation": "3: The model answer provides detailed information about EGFR突变的耐药机制和治疗切换原则，但未直接回答必须完成当前系统治疗后才能更换靶向药物这一核心问题，且部分内容超出题目范围，存在一定偏离和遗漏。"
  },
  "150": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers both systemic therapy and whole-brain radiotherapy, with appropriate rationale and clinical details. However, it places more emphasis on systemic therapy as the initial step, whereas the reference answer prioritizes palliative whole-brain radiotherapy for symptom control, making this a minor deviation from the reference's clinical priority."
  },
  "151": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale for switching to RET-targeted therapy but omits the guideline-supported option of completing the current first-line and maintenance therapy, which is also acceptable. It presents only one approach as preferred, missing the nuance and flexibility recommended in the reference answer."
  },
  "152": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it introduces extra detail about trial data, HER2 mutation confirmation, and ILD risk, which, while relevant, are not required by the reference answer. It also slightly overemphasizes the need for caution in squamous histology, whereas the reference answer states no additional histologic or molecular prerequisites are needed."
  },
  "153": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and structured approach, including differential diagnosis and individualized management, but it does not directly recommend increasing the frequency of imaging follow-up as the reference answer does. Instead, it suggests targeted re-evaluation and short-term re-imaging only if the diagnosis is unclear, which partially aligns but omits the clear directive to increase surveillance frequency for any new imaging abnormality."
  },
  "154": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, evidence-based discussion, but it introduces nuanced recommendations (如“按需药物”而非“常规药物干预”)，并强调个体化和阶段性支持，略有偏离参考答案“常规提供”药物与咨询的绝对表述。"
  },
  "155": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes immediate systemic therapy, misclassifying the stage as IV despite the scenario describing a solitary, locally controlled brain metastasis (oligometastatic disease), where local control of the primary and regional nodes should be prioritized. This represents a notable error in clinical reasoning, despite some accurate supporting details."
  },
  "156": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, guideline basis, and practical considerations, matching the reference answer in content and accuracy, with no major omissions or errors."
  },
  "157": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately reflecting guideline recommendations, rationale, and exceptions, with no major omissions or errors."
  },
  "158": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the need to wait for molecular testing before systemic therapy, the rationale, and exceptions for urgent cases. However, it introduces some details (e.g., non-squamous NSCLC, specific drugs) that are not directly relevant to pure squamous cell carcinoma, and slightly overcomplicates the answer compared to the reference."
  },
  "159": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns with current international guidelines, but it omits the reference answer’s emphasis on the potential risk of early recurrence being missed if surveillance is reduced too early, and does not address the specific Chinese or local practice standards referenced in the original answer."
  },
  "160": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately reflects the reference answer, correctly stating that 12-month follow-up is standard even with COPD, and that more intensive surveillance is not routinely recommended. It adds some nuanced clinical considerations and patient communication points, but these are minor expansions rather than omissions; no major errors are present."
  },
  "161": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding, referencing current guidelines and evidence. However, it introduces additional stratification and individualized considerations not explicitly stated in the reference answer, and does not as clearly state that the described follow-up is insufficient for all IIIA patients, which is a key point in the reference."
  },
  "162": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors. It thoroughly addresses the clinical scenario, safety considerations, and guideline-based recommendations."
  },
  "163": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage, correctly noting the general follow-up frequency and some special considerations, but it inaccurately states that the frequency is the same as the surgical group, missing the key point that guidelines recommend more frequent imaging (every 3–6 months) after radiotherapy."
  },
  "164": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and even expands on relevant details without introducing inaccuracies."
  },
  "165": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional detail, and correctly emphasizes that routine brain MRI or PET/CT is not recommended without symptoms or strong suspicion of recurrence, aligning with current guidelines."
  },
  "166": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed information but directly contradicts the reference answer by stating that erlotinib, gefitinib, or dacomitinib are not recommended as first-line therapy for S768I single mutation, whereas the reference answer affirms their use. This is a notable error in clinical content."
  },
  "167": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing concurrent chemoradiotherapy, referencing guidelines, evidence, toxicity considerations, and the need for individualized assessment, with no major omissions or errors."
  },
  "168": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical reasoning, prioritizing local palliative therapy in the presence of endobronchial obstruction even with mild symptoms and imaging progression. However, it introduces additional considerations (e.g., risk of systemic spread, multidisciplinary input) and nuances not present in the reference, which, while not incorrect, slightly diverge from the directness and focus of the reference answer."
  }
}